NCT07354646 The Application of T1 Mapping in Real-World
| NCT ID | NCT07354646 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Condition | Myocardial Infarction (MI) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2020-03-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2020-03-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are: What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler "native T1" measurement (without contrast dye) instead of the more complex "ECV" measurement (which requires contrast dye) for diagnosis? Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping
Eligibility Criteria
Inclusion Criteria: 1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines. 2. Specific disease categories include: * Cardiomyopathies (HCM, DCM, RCM, ACM) * Infiltrative disorders (cardiac amyloidosis, Fabry disease) * Inflammatory conditions (acute/chronic myocarditis) * Ischemic heart disease (acute/chronic MI) * Valvular heart disease (aortic stenosis) * Arrhythmic conditions (atrial fibrillation) * Metabolic disorders (iron-overload) * Neoplastic conditions (cardiac tumors) * Congenital heart disease * Post-transplant evaluation 3. All diagnoses must be confirmed using established guideline-based criteria: * Echocardiographic parameters meeting disease-specific cutoffs * Cardiac MRI findings consistent with current consensus criteria * Laboratory biomarkers supporting respective diagnoses * Histopathological confirmation when clinically indicated Exclusion Criteria: * Presence of multiple cardiomyopathy diseases or risk factors simultaneously * Contraindications to CMR examination * Poor image quality precluding accurate T1 mapping analysis * Incomplete clinical data for definitive diagnosis confirmation * Pregnancy or lactation * Inability to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07354646 clinical trial?
This trial is open to participants of all sexes, studying Myocardial Infarction (MI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07354646 currently recruiting?
Yes, NCT07354646 is actively recruiting participants. Contact the research team at zhy_dreamer@163.com for enrollment information.
Where is the NCT07354646 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07354646 clinical trial?
NCT07354646 is sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 2,000 participants.